Clinical Trials

Clinical Trials for MTG5

Filter list of Clinical Trials

TopicTrial name of investigational drugClinical Trial ID(s)StatusOrphaCodeLink
Idiopathic Short StatureA 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height (ZomaTrip)
  • NCT00840944
  • ongoing
Small for Gestational AgeREAL 5
  • 2018-000232-10
  • ongoing
Small for Gestational AgeEffect of Insulin Sensitization on IGF-1 Response to Growth Hormone in SGA Children
  • NCT02931591
  • completed
Bardet Biedl Syndrome (BBS) Alström Syndrome (AS)Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity Phase 3
  • NCT03746522
  • concluded
  • OPRHA240371
  • OPRHA64
  • ORPHA110
Genetic ObesitySetmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
  • NCT03651765
  • ongoing
  • recruiting
  • OPRHA240371
  • OPRHA64
  • ORPHA110
AchondroplasiaA Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
  • NCT03197766
  • completed
  • ORPHA15
Genetic ObesitySetmelanotide for the Treatment of LEPR Deficiency Obesity
  • NCT03287960
  • concluded
  • ORPHA179494
Transition,paediatric chronic endocrine disordersGrowing up With the Young Endocrine Support System (YESS!) (YESS)
  • NCT04252001
  • ongoing
  • ORPHA418
  • ORPHA174590
  • ORPHA881
  • ORPHA95488
  • ORPHA85138
  • ORPHA754
  • ORPHA9571
  • ORPHA95494
Genetic ObesitySetmelanotide for the Treatment of Early-Onset POMC Deficiency Obesity
  • NCT 02896192
  • concluded
  • ORPHA71526
Genetic ObesityLong Term Extension Trial of Setmelanotide
  • NCT 03013543
  • ongoing
  • ORPHA71526
Genetic ObesityRM-493-22 (A Phase 2, Two-Stage (Open-Label Run-in Followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled Study of Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway)
  • NCT04963231
  • concluding
  • ORPHA71529
Prader-Willi SyndromeEffect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome
  • NCT02527200
  • ongoing
  • ORPHA739
Prader-Willi SyndromeZEPHYR Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome (ZEPHYR
  • NCT03790865
  • Terminated
  • ORPHA739
Prader-Willi SyndromeOxytocin Treatment in Neonates and Infants With Prader-Willi Syndrome (OTBB3)
  • NCT04283578
  • ongoing
  • ORPHA739
Prader-Willi SyndromeOTBB3 Long-term Interventional Follow-up Study up to 4 Years of Age of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial and Comparison With an Untreated Cohort of Children With Prader-Willi Syndrome
  • NCT05032326
  • Recrutiing
  • ORPHA739
Prader-Willi SyndromeOXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME: A STUDY OF THE SAFETY AND EFFICACY ON ORAL AND SOCIAL SKILLS AND FEEDING BEHAVIOR OF INTRANASAL ADMINISTRATIONS OF OXYTOCIN VS. PLACEBO (PHASE III CLINICAL TRIAL)
  • Number EudraCT 2019-002385- 12
  • Active
  • ORPHA739
Prader-Willi SyndromeLong-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial (OTBB3-FU)
  • Number EudraCT 2020-006161-11
  • Active
  • recruiting
  • ORPHA739
TopicTrial name of investigational drugClinical Trial ID(s)StatusOrphaCodeLink

An overview of all Clinical Trials can be found here.